Stock Track | Integra LifeSciences Plunges 5.44% in Pre-market on Disappointing Q4 Results and Weak Guidance

Stock Track

Feb 25, 2025

Integra LifeSciences Holdings Corp. (IART) experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.

The company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share (EPS) of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshadowed the earnings beat.

For the first quarter of 2025, Integra LifeSciences expects revenue in the range of $375 million to $385 million, well below analyst estimates of around $411.7 million. The company also guided for adjusted EPS between $0.40 and $0.45 for the quarter.

Furthermore, the company's full-year 2025 revenue guidance of $1.65 billion to $1.71 billion fell slightly short of analyst expectations of around $1.71 billion, adding to investor concerns about the company's growth prospects.

Analysts cited the weaker-than-anticipated revenue guidance as the primary reason for the stock's pre-market decline, as investors reevaluated Integra LifeSciences' near-term growth trajectory and potential headwinds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1185303225"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185303225\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185303225?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185303225","market":"hk","top_or_hot":-1,"title":"Stock Track | Integra LifeSciences Plunges 5.44% in Pre-market on Disappointing Q4 Results and Weak Guidance","media":"Stock Track","content":"<p>Integra LifeSciences Holdings Corp. (IART) experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.</p>\n\n<p>The company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share (EPS) of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshadowed the earnings beat.</p>\n\n<p>For the first quarter of 2025, Integra LifeSciences expects revenue in the range of $375 million to $385 million, well below analyst estimates of around $411.7 million. The company also guided for adjusted EPS between $0.40 and $0.45 for the quarter.</p>\n\n<p>Furthermore, the company's full-year 2025 revenue guidance of $1.65 billion to $1.71 billion fell slightly short of analyst expectations of around $1.71 billion, adding to investor concerns about the company's growth prospects.</p>\n\n<p>Analysts cited the weaker-than-anticipated revenue guidance as the primary reason for the stock's pre-market decline, as investors reevaluated Integra LifeSciences' near-term growth trajectory and potential headwinds.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Integra LifeSciences Plunges 5.44% in Pre-market on Disappointing Q4 Results and Weak Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Integra LifeSciences Plunges 5.44% in Pre-market on Disappointing Q4 Results and Weak Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Integra LifeSciences Holdings Corp. (IART) experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.</p>\n\n<p>The company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share (EPS) of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshadowed the earnings beat.</p>\n\n<p>For the first quarter of 2025, Integra LifeSciences expects revenue in the range of $375 million to $385 million, well below analyst estimates of around $411.7 million. The company also guided for adjusted EPS between $0.40 and $0.45 for the quarter.</p>\n\n<p>Furthermore, the company's full-year 2025 revenue guidance of $1.65 billion to $1.71 billion fell slightly short of analyst expectations of around $1.71 billion, adding to investor concerns about the company's growth prospects.</p>\n\n<p>Analysts cited the weaker-than-anticipated revenue guidance as the primary reason for the stock's pre-market decline, as investors reevaluated Integra LifeSciences' near-term growth trajectory and potential headwinds.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IART","symbol_name":"英特格拉生命科学","start_time":0,"source_url":"","article_id":"1185303225","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185303225","pubTimestamp":1740493844,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Integra LifeSciences Holdings Corp.  experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.The company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share  of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IART":"英特格拉生命科学"},"translate_title":"股票赛道Integra LifeSciences盘前暴跌5.44%，原因是第四季度业绩令人失望且指引疲弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IART":1},"content_text":"Integra LifeSciences Holdings Corp. (IART) experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.\nThe company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share (EPS) of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshadowed the earnings beat.\nFor the first quarter of 2025, Integra LifeSciences expects revenue in the range of $375 million to $385 million, well below analyst estimates of around $411.7 million. The company also guided for adjusted EPS between $0.40 and $0.45 for the quarter.\nFurthermore, the company's full-year 2025 revenue guidance of $1.65 billion to $1.71 billion fell slightly short of analyst expectations of around $1.71 billion, adding to investor concerns about the company's growth prospects.\nAnalysts cited the weaker-than-anticipated revenue guidance as the primary reason for the stock's pre-market decline, as investors reevaluated Integra LifeSciences' near-term growth trajectory and potential headwinds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}